LY2157299 Galunisertib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：LY2157299 Galunisertib	Purity：98% min
CAS NO：700874-72-2	Solubility：DMSO : ≥ 47 mg/mL (127.23 mM)
Molecular Formula：C₂₂H₁₉N₅O	Package：Package according to customer requirements
Molecular Weight：369.41916	Storage：Store at -20℃

Quality control

COA

Remarks

Galunisertib, also known as LY2157299, is a novel selective small molecule transforming growth factor beta receptor (TGF-βR) kinase inhibitor. LY2157299 inhibited HCC cell migration on Laminin-5, Fibronectin, Vitronectin, Fibrinogen and Collagen-I and de novo phosphorylation of pSMAD2. LY2157299 inhibited HCC migration and cell growth independently of the expression levels of TGF-βRII.

TGF-beta/Smad Inhibitors Related Products:

SB431542; LDN-193189; LY2109761; SB525334; SB-505124; GW788388; LY364947; RepSox; K02288; A-83-01; LDN-212854; PD169316; ITD-1; LY3200882; Dorsomorphin; Dorsomorphin 2HCl; Kartogenin

References

[1]. Cong L, et al. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy. Arch Pharm (Weinheim). 2014 Sep;347(9):609-15.

[2]. Serova M, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015 Aug 28;6(25):21614-27